LungLifeAI Logo

Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Description of the Business

Names of the directors, biographical details and responsibilities

Corporate governance

Country of incorporation / operation

Shareholder Information

  • Other Exchanges and Trading Platforms
  • Shares in Issue
  • Significant Shareholdings
  • Director Shareholdings
  • Shares Not in Public Hands
  • Restrictions in Transfer of AIM Securities
  • UK City Code on Takeovers and Mergers

Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

September 4, 2024

Data Supporting LungLB to be Presented at the Association for Molecular Pathology

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to announce that our two abstract submissions to the Association for Molecular Pathology1 (AMP) have beenaccepted for both presentation at their flagship 2024 Annual Meeting & Expo in Vancouver, BC, Canada from November 19-23rd, and also for publication in the […]
• Read More
August 22, 2024

LLAI Interim Results 2024

LungLife AI, Inc. (the “Company” or “LungLife”)   Half-year Report   LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces its unaudited half-year report for the six months ended 30 June 2024.    Strong progress with our LungLB® product   Continued operational delivery :  Financial Highlights:  Commenting Paul Pagano, Chief Executive […]
• Read More
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down